
Mycoplasma pneumoniae cells, small bacteria that are naturally adapted to the human lung.
Credit: María Lluch / CRG
Researchers at the Center for Genomic Regulation (CRG) and Pulmobiotics SL have created the first ‘living medicine’ to treat antibiotic-resistant bacteria growing on the surfaces of medical implants. The researchers created the treatment by removing a common bacteria’s ability to cause disease and repurposing it to attack harmful microbes instead.
The experimental treatment was tested on infected catheters in vitro, ex vivo and in vivo, successfully treating infections across all three testing methods. According to the authors, injecting the therapy under the skin of mice treated infections in 82% of the treated animals.
The findings are an important first step for the development of new treatments for infections affecting medical implants such as catheters, pacemakers and prosthetic joints. These are highly resistant to antibiotics and account for 80% of all infections acquired in hospital settings.
The study is published today in the journal Molecular Systems Biology . This work has been supported by the “la Caixa” Foundation through the CaixaResearch Health call, the European Research Council (ERC), the MycoSynVac project under the EU’s Horizon 2020 research and innovation program, the Generalitat de Catalunya and the Instituto de Salud Carlos III .
The new treatment specifically targets biofilms, colonies of bacterial cells that stick together on a surface. The surfaces of medical implants are ideal growing conditions for biofilms, where they form impenetrable structures that prevent antibiotics or the human immune system from destroying the bacteria embedded within. Biofilm-associated bacteria can be a thousand times more resistant to antibiotics than free-floating bacteria.
Staphylococcus aureus is one of the most common species of biofilm-associated bacteria. S. aureus infections do not respond to conventional antibiotics, requiring patients to surgically remove any infected medical implants. Alternative therapies include the use of antibodies or enzymes, but these are broad-spectrum treatments that are highly toxic for normal tissues and cells, causing undesired side effects.
The authors of the study hypothesized that introducing living organisms that directly produce enzymes in the local vicinity of biofilms is a safer and cheaper way of treating infections. Bacteria are an ideal vector, as they have small genomes that can be modified using simple genetic manipulation.
The researchers chose to engineer Mycoplasma pneumoniae, a common species of bacteria that lacks a cell wall, making it easier to release the therapeutic molecules that fight infection while also assisting it in evading detection from the human immune system. Other advantages of using M. pneumoniae as a vector include its low risk of mutating new abilities, and its inability to transfer any of its modified genes to other microbes living nearby.
M. pneumoniae was first modified so that it would not cause illness. Further tweaks made it produce two different enzymes that dissolve biofilms and attacks the cell walls of the bacteria embedded within. The researchers also modified the bacteria so that it secretes antimicrobial enzymes more efficiently.
The researchers first aim to use the modified bacteria to treat biofilms building around breathing tubes, as M. pneumoniae is naturally adapted to the lung. “Our technology, based on synthetic biology and live biotherapeutics, has been designed to meet all safety and efficacy standards for application in the lung, with respiratory diseases being one of the first targets. Our next challenge is to address high-scale production and manufacturing, and we expect to start clinical trials in 2023, ”says María Lluch, co-corresponding author of the study and Chief Science Officer of Pulmobiotics.
The modified bacteria may also have long-term applications for other diseases. “Bacteria are ideal vehicles for ‘living medicine’ because they can carry any given therapeutic protein to treat the source of a disease. One of the great benefits of the technology is that once they reach their destination, bacterial vectors offer continuous and localized production of the therapeutic molecule. Like any vehicle, our bacteria can be modified with different payloads that target different diseases, with potentially more applications in the future, ”says ICREA Research Professor Luis Serrano, Director of the CRG and co-author of the study.
Original Article: Researchers create ‘living medicine’ to treat drug-resistant infections
More from: Center for Genomic Regulation
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Living medicine
- The Best Medicine for Healthcare Workers: A Living Wageon April 1, 2023 at 1:35 pm
Senate Bill 525 (SB 525), introduced by state senator Maria Elena Durazo (D), would increase the minimum wage for healthcare workers in California to $25 an hour and tie it to inflation (the current ...
- Sofinnova Partners dives into digital medicine, funds new companieson March 31, 2023 at 5:43 am
European life sciences venture capital firm Sofinnova Partners, has launched a new investment strategy focused on digital medicine.
- Your Guide To Assisted Living In San Francisco In 2023on March 31, 2023 at 5:05 am
With top-ranking health care facilities, iconic scenery and proximity to nature, San Francisco is an appealing retirement destination that’s home to a wide variety of senior living options. It’s also ...
- Medicine price setting might appeal to voters but will cost patientson March 31, 2023 at 3:00 am
As policymakers search for potential cuts to the national budget, they risk jeopardizing the country’s most cost-effective use of healthcare dollars: biomedical innovation regarding vaccines, ...
- What Is Independent Living? Benefits, Types And Costson March 31, 2023 at 12:06 am
in addition to independent living, says Joseph G, Ouslander, M.D., professor of geriatric medicine and associate dean of geriatrics at the Charles E. Schmidt College of Medicine at Florida ...
Go deeper with Google Headlines on:
Living medicine
[google_news title=”” keyword=”living medicine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antibiotic-resistant bacteria treatment
- Multiple Drug Resistance Bacterial Infection Treatment Market Trends by Forecast to 2028on March 31, 2023 at 6:05 pm
Mar 31, 2023 (Heraldkeepers) -- The Insight Partners Latest Research on “Multiple Drug Resistance Bacterial Infection Treatment Market Forecast to 2028″ Includes Covid-19 Impact and Global Analysis – ...
- Study reveals wastewater as potential origin for mobile antibiotic resistance geneson March 30, 2023 at 5:16 am
researchers in Sweden found new evidence favoring the hypothesis that wastewaters and wastewater treatment plants (WWTPs) presented a feasible environment for mobilizing antibiotic resistance ...
- 2023 Multiple Drug Resistance Bacterial Infection Treatment Market: Best Practices of Top Players and Business Success Plans till 2030on March 29, 2023 at 8:18 pm
Multiple Drug Resistance Bacterial Infection Treatment Market” information for each competitor includes (Abbott Laboratories Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research Inc., ...
- Is Fomepizole the Key to Overcoming Antibiotic-Resistant Pneumonia?on March 29, 2023 at 7:10 pm
Increases in multidrug-resistance in the bacteria Streptococcus pneumoniae ... "We also evaluated whether fomepizole treatment impacted the antibiotic susceptibility of other anaerobic gram ...
- Study offers a novel therapeutic option to combat antibiotic-resistant pneumoniaon March 29, 2023 at 12:07 pm
Increases in multidrug-resistance in the bacteria Streptococcus pneumoniae ... "We also evaluated whether fomepizole treatment impacted the antibiotic susceptibility of other anaerobic gram ...
Go deeper with Google Headlines on:
Antibiotic-resistant bacteria treatment
[google_news title=”” keyword=”antibiotic-resistant bacteria treatment” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]